Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma
- 1 July 2000
- journal article
- Published by American Society of Hematology in Blood
- Vol. 96 (1), 355-357
- https://doi.org/10.1182/blood.v96.1.355
Abstract
In the present study, we used a polymerase chain reaction–based (PCR-based) strategy to retrospectively analyze the presence of residual myeloma cells in serial posttransplant bone marrow samples obtained from 13 patients in remission after allogeneic hemopoietic stem cell transplantation (allo SCT). For this purpose, patient-specific primers were generated from complementarity determining regions 2 and 3 of the rearranged IgH gene. The level of sensitivity of the PCR-based assay ranged from 1 in 105 to 1 in 106 normal marrow cells. Following transplantation, 9 of 12 patients who attained stringently defined complete remission (CR) remained persistently PCR− for a median of 36 months, and 4 of the patients remained PCR− up to the latest analysis, which was performed at 48, 72, 72, and 120 months, respectively, after allo SCT. None of the patients in the PCR− subgroup experienced a disease relapse, and only 1 of 4 PCR+ patients experienced a relapse. It is concluded that allo SCT has the potential ability to induce sustained serological and molecular CR in selected patients with multiple myeloma.Keywords
This publication has 16 references indexed in Scilit:
- Selection and transplantation of autologous CD34+ B‐lineage negative cells in advanced‐phase multiple myeloma patients: a pilot studyBritish Journal of Haematology, 1999
- Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: a case reportBone Marrow Transplantation, 1999
- Molecular and Clinical Remissions in Multiple Myeloma: Role of Autologous and Allogeneic Transplantation of Hematopoietic CellsJournal of Clinical Oncology, 1999
- Graft-versus-myelomaBone Marrow Transplantation, 1998
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myelomaBone Marrow Transplantation, 1998
- A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumorsLeukemia, 1997
- Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma.Journal of Clinical Oncology, 1995
- Allogeneic Bone Marrow Transplantation in Multiple MyelomaNew England Journal of Medicine, 1991
- Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and stagingBritish Journal of Haematology, 1982